Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Roche, Trimeris Halt Clinical Trials of New Fusion Inhibitor T-1249

January 7, 2004

Swiss drug maker Roche and U.S. biotechnology company Trimeris on Monday announced that they have halted clinical trials of their experimental antiretroviral drug T-1249, Reuters reports. The two companies developed a similar antiretroviral drug called Fuzeon, which received FDA approval in March 2003 (Pierson/Berkrot, Reuters, 1/6). Fuzeon, which is in a new class of drugs called fusion inhibitors, has encountered resistance from doctors and patients because of its high cost and injection delivery method. The drug costs about $20,000 per patient per year -- double the price of the next most expensive HIV treatments currently on the market. The drug is designed for HIV/AIDS patients who have failed to respond to other medications (Kaiser Daily HIV/AIDS Report, 10/17/03). Roche and Trimeris said that trials of T-1249, which the FDA had agreed to "fast-track" after later trials were completed, were stopped because of problems in the drug's formulation (Reuters, 1/6). "We didn't feel confident we could reproduce it at a large scale," Roche said, according to the Financial Times (Firn, Financial Times, 1/7). However, the companies did not describe the problems, Reuters reports. The companies said that they are still committed to developing fusion inhibitors and signed an agreement to continue research on such drugs, according to Reuters (Reuters, 1/6). In addition, the companies are researching ways to reduce the number of times Fuzeon must be injected from twice a day to once a week or once a month, according to the Raleigh News & Observer (Vollmer, Raleigh News & Observer, 1/6).

Back to other news for January 7, 2004


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2003 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More HIV News

Tools
 

Advertisement